Uploaded on Dec 5, 2022
According to the new market research report "Multiplex Assays Market by product (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence, Application (R&D, Diagnosis), End User (Pharma & Biotech, Hospital) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 4.3 billion by 2026 from USD 3.0 billion in 2021, at a CAGR of 7.6% during the forecast period. Browse in-depth TOC on "Multiplex Assays Market" 246 – Tables 38 – Figures 266 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314 The increasing adoption of companion diagnostics and the rising need for effective analytical platforms in research and clinical diagnostics to reduce the operational costs and the time taken for diagnosis are the major factors driving the market growth.
Multiplex Assays Market - How The Market Will Witness Substantial Growth In The Upcoming Years
MarketsandMarkets
Presents
Multiplex Assays Market worth $4.3 billion by 2026
https://www.marketsandmarkets.com/Market-Reports/multiplex-assays-market-61593314.ht
ml
The report "Multiplex Assays Market by product (Consumables, Instruments, Software &
Services), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence,
Application (R&D, Diagnosis), End User (Pharma & Biotech, Hospital) - Global Forecast to 2026",
is projected to reach USD 4.3 billion by 2026 from USD 3.0 billion in 2021, at a CAGR of 7.6%
during the forecast period.
The increasing adoption of companion diagnostics and the rising need for effective analytical
platforms in research and clinical diagnostics to reduce the operational costs and the time taken
for diagnosis are the major factors driving the market growth.
• Product and Service accounted for the largest share of the multiplex assays market and is
expected to grow at the highest CAGR
• Protein-based multiplex assays segment is expected to account for the largest share of the
global multiplex assays market and is expected to grow at the highest CAGR
• Flow cytometry segment is expected to account for the largest share of the global multiplex
assays market and is expected to grow at the highest CAGR
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownload
Objectives of the Study:
• To define, describe, and forecast the global multiplex assays market based on the product &
service, type, technology, application, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the
market (such as drivers, restraints, opportunities, and challenges)
• To strategically analyse micromarkets with respect to individual growth trends, prospects,
and contributions to the overall multiplex assays market
• To analyse opportunities in the market for stakeholders and provide details of the
competitive landscape for market leaders
• To forecast the size of the market segments with respect to five main regions, namely, North
America, Europe, Asia Pacific, and the Rest of the World
• To strategically profile the key players and comprehensively analyse their product portfolios,
market positions, and core competencies
• To track and analyse competitive developments such as acquisitions, product launches,
expansions, agreements, partnerships, and R&D activities in the multiplex assays market.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst
This report categorizes the multiplex assays market into the
following segments and subsegments:
By Product and Service
• Consumables
• Instruments
• Software and Services
By Type
• Protein Multiplex Assays
• Nucleic Acid Multiplex Assays
• Cell-Based Multiplex Assays
By Technology
• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-Time PCR
• Other Technologies
By Application
• Research & Development
• Clinical Diagnostics
Luminex Corporation (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc (US), Bio-Rad
Laboratories, Inc. (US), Qiagen N.V. (Netherlands), Abcam plc (UK), Becton, Dickinson
and Company (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Meso Scale
Diagnostics (US), Randox Laboratories (UK), Quanterix (US), Bio-Techne Corporation
(US), Olink (Sweden), DiaSorin S.p.A. (Italy), Seegene (South Korea), Promega
Corporation (US), Siemens Healthineers (Germany), PerkinElmer, Inc. (US), Shimadzu
Biotech (Japan), Antigenix America, Inc. (US), Enzo Life Sciences, Inc. (US), Boster
Biological Technology (US), AYOXXA Biosystems GmbH (Germany), and Cayman Chemical
Company (US).
Company Insights
Illumina, Inc. (US) is one of the leading players in the Multiplex Assays Market. The company has
a strong geographic presence across the US, Europe, Greater China, and the Asia Pacific. The
company focuses on offering consumables and analyzers in the multiplex assays market. Illumina
concentrates on inorganic strategies to maintain its leadership position in this market. The
company has signed several collaborations and partnerships with other
companies/organizations, which are expected to strengthen the foothold of the company in the
domain of next-generation sequencing (NGS) and multiplex sequencing.
Luminex Corporation (US) is one of the leading players in the Multiplex Assays Market. Luminex
focuses on product launches and developments to enhance its position in the market. The
company has the EUA by the US FDA for multiplex COVID-19 assays.
Bio-Rad Laboratories, Inc. (US) is one of the leading players in the Multiplex Assays Market. The
company has a wide geographical presence in the US, Singapore, China, the UK, Belgium,
Switzerland, France, and Germany. The company has a strong R&D and manufacturing in the
area of specialty chemicals and clinical diagnostics. The company has received the EUA from the
US FDA for several COVID-19 multiplex assays.
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
Currently servicing 5000 customers worldwide including 80% of global Fortune 1000
companies as clients. Almost 75,000 top officers across eight industries worldwide
approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high
growth markets following the "Growth Engagement Model – GEM". The GEM aims at
proactive collaboration with the clients to identify new opportunities, identify most
important customers, write "Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors. MarketsandMarkets™
now coming up with 1,500 MicroQuadrants (Positioning top players across leaders,
emerging companies, innovators, strategic players) annually in high growth emerging
segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies
this year for their revenue planning and help them take their innovations/disruptions
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform,
"RT" connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche markets.
Contact Us
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road, Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
[email protected]
Press release:
https://www.marketsandmarkets.com/PressReleases/multiplex-assay
s.asp
Research insights:
https://www.marketsandmarkets.com/ResearchInsight/multiplex-assa
ys-market.asp
Comments